Read our latest news, and find more about us and our portfolio companies.
Please visit our investor relations section to review the latest information
Arix
23rd June 2023
Portfolio company Disc Medicine raises $157.8 million in public offering
9th June 2023
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
16th May 2023
Portfolio company Ensoma announces closing of Series B Extension
26th April 2023
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
25th April 2023
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report and Notice of Annual General Meeting
18th April 2023
Harpoon Therapeutics Presents Preclinical Results for Novel T Cell Engagers HPN217 and HPN328 at AACR 2023
14th February 2023
Portfolio company Disc Medicine announces $62.5 million financing
5th January 2023
Twelve Bio to be acquired alongside $85 million financing of Ensoma co-led by Arix to create best-in-class engineered cell therapy platform
30th December 2022
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
14th October 2022
Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
10th August 2022
Arix Portfolio Company Artios Initiates Phase 2 Study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
Arix Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
Changes to Board of Directors
Arix Bioscience Announces Interim Results for the Six Months Ended 30 June 2022
22nd December 2021
Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals
15th December 2021
Depixus raises €30.6M (£26.1 million) in Series A Financing
8th November 2021
Arix Managing Director to Participate in Fireside Chat at the Jefferies Healthcare Conference
18th October 2021
Business Update and Cancellation of Share Buyback
6th October 2021
Board Changes
2nd September 2021
Arix participates in $90 million Series B financing for Disc Medicine
28th April 2021
Amplyx Pharmaceuticals acquired by Pfizer
Portfolio Company
9th March 2021
Arix founds new portfolio company Twelve Bio
18th December 2020
Completion of sale of VelosBio
3rd December 2020
Artios and Merck KGaA announce global strategic collaboration
5th November 2020
VelosBio to be acquired by Merck for $2.75 billion
9th June 2020
Arix to present at Proactive One2One Biotech Forum
8th June 2020
Arix announces strategic and operational update
3rd June 2020
Arix to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
20th May 2020
Amplyx closes $53 million Series C extension
12th May 2020
Notice of Annual General Meeting
15th April 2020
Investment team changes
12th March 2020
Imara prices Nasdaq IPO
9th March 2020
Arix names Dr Roberto Iacone as Entrepreneur in Residence
27th January 2020
Arix co-founds Quench Bio with Series A financing
3rd October 2019
Arix 2019 Capital Markets Day
30th September 2019
Arix co-leads EUR 20 million Series A investment round in STipe Therapeutics
13th September 2019
Imara announces confidential submission of draft registration statement for proposed US IPO
28th August 2019
Interim results for the six months ended 30 June 2019
2nd April 2019
Aura completes $40 million Series D financing
28th March 2019
Annual Results for the year ended 31 December 2018
Arix Bioscience plc Board changes
18th March 2019
Arix co-leads $63 million Series B investment round for Imara
19th February 2019
Management and Board changes
14th February 2019
Harpoon closes initial public offering
8th February 2019
Harpoon prices Nasdaq IPO
29th January 2019
Update on Harpoon proposed IPO in the United States
28th December 2018
Harpoon announces proposed public offering in the United States
11th December 2018
Arix appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)
1st October 2018
Arix Bioscience Co-leads $58 million Series A investment round for VelosBio
13th September 2018
Arix Bioscience Plc announces Board changes
4th September 2018
Changes announced to executive team to accelerate growth and strategy
10th August 2018
Artios completes £65m Series B investment round
31st May 2018
Arix Bioscience forms strategic collaboration with Evotec AG and Fred Hutchinson Cancer Research Center to foster new companies in cancer and infectious diseases
Lord John Hutton steps down from Board of Directors of Arix Bioscience plc
5th April 2018
Arix Bioscience to present at H.C. Wainwright & Co. Global Life Sciences Conference on 10 April 2018
19th February 2018
Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients
21st December 2017
Arix Bioscience co-leads $30 million financing for Aura Biosciences
25th May 2017
Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics
28th April 2017
Maiden Annual Results 2016
21st September 2016
Arix supports Artios Pharma, a new biotech company focused on DNA damage response
25th July 2016
Arix Bioscience supports Depixus, an early-stage company focused on nucleic acid sequencing & epigenetic analysis